- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02997982
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease (VALZ-Pilot)
Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot)
Study Overview
Status
Intervention / Treatment
Detailed Description
This study investigates the effects of valaciclovir treatment to individuals with Alzheimer's disease (AD) or Mild Cognitive Impairment of Alzheimer's Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of oral valaciclovir treatment. To find 36 persons fulfilling inclusion criteria, up to 120 persons will be screened. Important inclusion criteria are Herpes Simplex Virus (HSV) Immunoglobulin G (IgG)-positivity (HSV carriage), Apolipoprotein E allele 4 carriage and sufficient kidney function (estimated glomerular filtration rate above 30 ml/min). All participants must give their informed consent to participation.
The valaciclovir dose will be 500 mg three times daily the first week and 1000 mg three times daily week 2-4.
Participants will be investigated using different measures before and after the treatment period: Mini Mental State Examination to assess cognitive function, Cerebrospinal fluid biomarkers of Alzheimer's disease and [18F]-FHBG-PET/CT (9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine positron emission tomography/computed tomography)) to possibly indicate active HSV infection within the central nervous system.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden
- Memory Clinic, Uppsala University Hospital
-
-
Västerbotten
-
Umeå, Västerbotten, Sweden, 90185
- Geriatric Centre, University Hospital in Umeå
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Man or women, age ≥ 65 years
- Ability to take a stand and to make and to sign an informed consent to participate in the study. This implies that a person with MMSE (Mini Mental State Examination) < 18 will probably not be included.
- Diagnosed with Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease. At least one brain imaging examination should have been done (CT, MR, SPECT or PET/CT) and at least one objective finding should support the diagnosis beyond specific medical history. Reduced perfusion or reduced metabolism bilaterally temporally, hippocampal atrophy or pathological markers for Alzheimer's disease in cerebrospinal fluid is such findings. Persons with vascular brain disorders e.g. severe white matter changes or previous brain infarction will not be included but those with white matter changes considered normal for their age can be included.
- Positive for anti-HSV (Herpes Simplex Virus) Immunoglobulin G (IgG) in plasma, i.e. carrier of HSV.
- Hetero or Homozygote for allele 4 of gene Apolipoprotein E.
- Stable over all medication including medication for Alzheimer's disease (rivastigmine, galantamin, donepezil or memantin) for at least one month.
- No known allergy or oversensitivity against valaciclovir or aciclovir.
- Ability to independently or by support from relative or other caretaker comply to study drug.
Exclusion Criteria:
- Renal insufficiency with estimated GFR (Glomerular Filtration Rate) ≤ 30 ml/min/1.73m2
- Ongoing treatment with anticoagulants (Warfarin, low molecular heparin or other anticoagulant agents). Antiplatelet agents in recommended dose are accepted (i.e. Acetylsalicylic acid 75 mgx1)
- Life expectancy < 1 year due to other comorbidity
- Ongoing severe somatic condition that might interfere with the patients participation in the study (i.e. ongoing cancer treatment)
- Ongoing illness that makes exams in a supine position impossible (i.e. severe heart failure, severe back pain).
- Dementia diagnosis other than Alzheimer's disease, including Vascular dementia.
- Other known neurological/neurodegenerative disorder (i.e. brain tumor, MS (Multiple sclerosis), ALS (amyotrophic lateral sclerosis))
- Claustrophobia or other contraindication for doing a PET/CT scanning.
- Depression or other psychiatric illness that requires treatment (i.e. severe psychosis or other illness with equal grade of seriousness)
- Dementia or cognitive dysfunction to such extent that an informed consent is impossible to obtain, corresponding to about MMSE-SR (Mini Mental State Examination-Swedish revision) <18.
- History of substance abuse (i.e. central nervous system stimulants or alcohol). Nicotine use is accepted.
- Not willing to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Valaciclovir treatment
Valaciclovir 500Mg Tablet
|
Valaciclovir treatment (oral, 500 mg tablets).
First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebrospinal fluid (CSF) Total Tau
Time Frame: Baseline and treatment day 28
|
Change in CSF Total Tau between samples taken before and after drug treatment
|
Baseline and treatment day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebrospinal fluid (CSF) Neurofilament light chain (NFL)
Time Frame: Baseline and treatment day 28
|
Change in CSF NFL between samples taken before and after drug treatment
|
Baseline and treatment day 28
|
Cerebrospinal fluid (CSF) phosphorylated Tau (p-Tau)
Time Frame: Baseline and treatment day 28
|
Change in CSF p-Tau between samples taken before and after drug treatment
|
Baseline and treatment day 28
|
Cerebrospinal fluid (CSF) Amyloid beta 1-42
Time Frame: Baseline and treatment day 28
|
Change in Amyloid beta 1-42 between samples taken before and after drug treatment
|
Baseline and treatment day 28
|
PET/CT: [18F]-FHBG accumulation within the central nervous system (CNS)
Time Frame: One week before drug treatment start
|
Can [18F]-FHBG-PET/CT detect replicating HSV infection within the CNS?
|
One week before drug treatment start
|
PET/CT: Location of [18F]-FHBG accumulation
Time Frame: One week before drug treatment start
|
Do [18F]-FHBG accumulation locate to brain areas affected in AD?
|
One week before drug treatment start
|
PET/CT: [18F]-FHBG accumulation
Time Frame: One week before and one week after drug treatment
|
Change in [18F]-FHBG accumulation after, as compared to before, drug treatment
|
One week before and one week after drug treatment
|
Mini Mental State Examination - Swedish Revision (MMSE-SR)
Time Frame: Baseline and treatment day 28
|
Change in MMSE-SR scores from baseline to after drug treatment
|
Baseline and treatment day 28
|
Cerebrospinal fluid (CSF) acyclovir concentration
Time Frame: Treatment day 28
|
Cerebrospinal fluid (CSF) acyclovir concentration
|
Treatment day 28
|
Cerebrospinal fluid (CSF) 9-carboxymethoxymethylguanine (CMMG) concentration
Time Frame: Treatment day 28
|
Concentration of CMMG, main acyclovir metabolite
|
Treatment day 28
|
Serum acyclovir concentration
Time Frame: Treatment day 28
|
Serum acyclovir concentration
|
Treatment day 28
|
Serum 9-carboxymethoxymethylguanine (CMMG) concentration
Time Frame: Treatment day 28
|
Concentration of CMMG, main acyclovir metabolite
|
Treatment day 28
|
Proportion completing the [18F]-FHBG-PET/CT investigations
Time Frame: For the investigations one week before and one week after drug treatment
|
Is [18F]-FHBG-PET/CT a feasible examination among persons with Alzheimer's disease
|
For the investigations one week before and one week after drug treatment
|
Proportion completing the 28 days treatment with valaciclovir at specified doses
Time Frame: Treatment day 28
|
Feasibility of valaciclovir treatment as measured by the number of participants completing the full treatment period at the specified dose
|
Treatment day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hugo Lövheim, M.D., Ph.D., Umea University, Umea, Sweden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Virus Diseases
- Infections
- Neurocognitive Disorders
- Neurodegenerative Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Dementia
- Tauopathies
- Cognition Disorders
- Herpesviridae Infections
- Alzheimer Disease
- Cognitive Dysfunction
- Herpes Simplex
- Anti-Infective Agents
- Antiviral Agents
- Valacyclovir
Other Study ID Numbers
- UmU-2016-390-31M
- 2016-002317-22 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Valaciclovir 500Mg Tablet
-
Heidelberg ImmunoTherapeutics GmbHCompletedHerpes GenitalisGermany
-
Tanta UniversityCompleted
-
Fortune Pharmacal Co., Ltd.Chinese University of Hong KongCompleted
-
Helwan UniversityCompleted
-
Chang Gung Memorial HospitalRecruiting
-
British Columbia Cancer AgencyBC Cancer Foundation; Pancreatic Cancer CanadaUnknownResectable Pancreatic Ductal AdenocarcinomaCanada
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
GlaxoSmithKlineCompleted
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Daewoong Pharmaceutical Co. LTD.Completed